HAWK Biosystems

Executive Summary

HAWK Biosystems, a Barcelona-based biotechnology company founded in 2018, is advancing spatial proteomics through its proprietary QF-Pro® technology. This patented platform enables precise quantification and spatial mapping of protein functions within tissue samples, offering clinically actionable insights for patient stratification, particularly in immuno-oncology. By moving beyond traditional bulk proteomics, HAWK aims to provide a more nuanced understanding of the tumor microenvironment, potentially improving treatment selection and response prediction. The company addresses a critical need in precision oncology, where spatial heterogeneity often limits therapeutic efficacy. Despite being in early stages with no disclosed funding rounds or revenue, HAWK's innovative approach positions it as a promising player in the diagnostic and biomarker discovery space. The technology has the potential to be integrated into clinical workflows, but it currently lacks published validation studies or regulatory clearances, highlighting the need for further development and partnerships. If successfully commercialized, QF-Pro could become a key tool for pharmaceutical companies and clinical labs seeking to enhance immuno-oncology drug development and patient outcomes. However, the company faces competition from established spatial proteomics platforms and must demonstrate robust analytical and clinical validity to gain market traction. The path to adoption will require rigorous validation, strategic collaborations, and significant capital investment.

Upcoming Catalysts (preview)

• Q4 2026Initial Clinical Validation Data in Immuno-Oncology40% success
• H2 2026Series A Funding Round50% success
• H1 2027Strategic Partnership with Major Pharma30% success